An observational study in Asthma and Eosinophilic Asthma, sponsored by Laval University. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-05.
Sponsored by Laval University · Observational
In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes. Of these, one of the most common is eosinophilic asthma, based on induced sputum differential cell count. Patients with severe asthma and an eosinophilic asthma phenotype have different pathophysiological characteristics than those seen in patients with with mild asthma. However, few studies have compared patients with eosinophilic phenotype according to the severity of asthma. In addition, the stability of the phenotype based on the sputum results has been criticized.
This study aims to describe the characteristics of patients with eosinophilic asthma phenotype according to the severity of asthma and determine the stability of the phenotype.
Characteristics of asthmatic subjects with sputum eosinophilia will be compared according to asthma severity.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 918 is above the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →Laval University is the lead sponsor of 371 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Asthmatic subjects from the Quebec city region.
With a proven diagnosis of asthma as defined by one of the above criteria of current guidelines (36):
A respirologist's current diagnosis of asthma found in the patient's medical report 3. Non-smokers or smokers/ex-smokers defined as someone with a smoking history \<10 pack-years 4. With sputum differential cell count result 5. Considered to receive optimal treatment for their disease (as per current guidelines except for patients included in exploratory objective 1.
Exclusion Criteria:
Asthmatic patients showing 3% or more sputum eosinophils
Asthmatic patients showing less than 3% sputum eosinophils
Asthma severity according to medication use
Prevalence of patients with 3% or more sputum eosinophils in mild, moderate and severe asthma
Time frame: Baseline
ACSS symptom sub-score
Comparison of asthma control between patients with 3% or more sputum eosinophils and patients with less than 3% sputum eosinophils
Time frame: Baseline
FEV1 percent predicted
Comparison of forced expiratory volume in one second between patients with 3% or more sputum eosinophils and patients with less than 3% sputum eosinophils
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laval University